Cye Cornelio

Congratulations 👏 to @JLHarrington_MD on winning our 7th Annual Pecha Kucha with her fantastic presentation,PREVENT the Perfect Storm: Managing Metabolic Syndrome! #AHA25

Rise and shine, #AHA25 Come check out the Heart Failure/Cardiomyopathy Annual Pecha Kucha! ⏰8AM / 📍260-262. This year, Pecha Kucha Says: It`s All About Cardiovascular-Kidney Metabolic Health. Join us to continue the conversation on CKM as speakers contend to earn your vote! 🏆

Pecha Kucha Sunday 8AM Room 261 @AHAScience on #CKM Syndrome #AHA25 #CardioX @DrMarthaGulati @AnastasiaSMihai @iamritu @hvanspall @Drroxmehran @Pooh_Velagapudi @hmartinjulien @SVRaoMD @mmamas1973 @purviparwani @rblument1 @pabeda1 @DavidWienerMD @KTamirisaMD & vote for Savage 😜

VESALIUS-CV trial: Adding evolocumab to LLRx significantly cuts LDL-C and lowers the risk of CV death/MI/ischemic stroke/ischemia-driven revasc at 4.5 years vs. placebo in high-risk patients without a prior MI or stroke. #AHA25 View the slides here: clinicaltrialresults.org/wp-content/upl…

Diuretics in AHF: 1.loop diuretics,if refractory> 2.combine with thiazide,if refractory> 3.add dopamine,dobutamine, milrinone 4. Ultrafiltration or hemodialysis(coexist renal failure) In case of low k+>add spironolactone In case of alkalosis>add acetazolamide From Braunwald

Join Dr. @AminYehyaMD and team as they shed light on the latest #epICD recommendations, examining everything from clinical trials to real-world scenarios, patient disparities, & future methodologies. Discover who could benefit most from an ICD. jacc.org/doi/10.1016/j.… #JACCHF #GDMT #HFrEF @AndrewJSauer @BiykemB @SanaAlkhatib9

In pts with HFrEF and hyperkalemia (K>5 mEq/L), sodium zirconium cyclosilicate improves optimizing the use of MRA and K levels, reduces risk of hyperkalemia and need to discontinue MRA. Slides from REALIZE-K trial presented here: clinicaltrialresults.org/wp-content/upl…

Sacubitril-Valsartan effective in reducing risk of cardiotoxicity in high risk pts undergoing anthracycline chemotherapy, 18% absolute risk reduction with Sacubitril-Valsartan vs placebo. Dr. Marcely Gimenes Bonatto shares results of SARAH trial clinicaltrialresults.org/wp-content/upl…

Congratulations to @EricAdler17 on winning this year’s Pecha Kucha Heart Failure session! Thanks to all our speakers for a great session!

Don’t miss @noshreza battle to defend her title in the 6th Annual Pecha Kucha Heart Failure Session at #AHA24! Join us for an entertaining session on infection, inflammation, and heart failure! 🦠🫀Who will be this year’s champion?🏆 @MarkDrazner @SherylChow

In the CLEAR randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years. Full trial results: nej.md/4i2U6dV

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes #AHA24| New England Journal of Medicine nejm.org/doi/full/10.10…

The complexities of telehealth in heart failure management highlighted by @colleenkmac at #AHA24. We need to develop interventions to overcome systemic barriers in the digital divide.

@RuthMCreber promotes implementation of interventions in heart failure across the frailty spectrum! #AHA24

@BidwellJT presents on a key aspect of heart failure care—the patient-provider dyad. Communication and provider trust in heart failure MATTERS and impacts patient outcomes! #AHA24

Happening now at #AHA Optimizing Heart Failure Through a Multidisciplinary approach! Learning more about international efforts to adopt GDMT from @batallah08 who established the FIRST pharmacist-led optimization clinics in the Middle East Gulf Region! #GDMTworks

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, and hepatomegaly. Treatments are improving. Full review: nej.md/4eHjGU3

1 in 5 adults have an Lp(a) level that is too high. Use #CardioSmart’s Lp(a) Infographic to help patients understand this condition and how it might affect their heart. bit.ly/40ys3ta #Cholesterol #ACC24

⚠️2024 @ACCinTouch Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction‼️ #PositionPaper #HFrEF #ACC

🏨 with HFrEF Only one at a time Go slow Defer to outpatient Be cautious What is the worst that can happen? Delay ARNI ➡️ 42% ⬆️ risk CV☠️/HF🏨 Delay BB ➡️ 25% ⬆️ risk ☠️ Delay MRA ➡️ 37% ⬆️ risk CV☠️/HF🏨 Delay SGLTi ➡️ 58% ⬆️ risk CV☠️/HF🏨/ER Urgency needed!